Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials

Objective: Tumor necrosis factor alpha inhibitors (TNFi) have shown substantial efficacy in alleviating and treating ankylosing spondylitis (AS). However, the heightened interest is accompanied by concerns over adverse events. In this meta-analysis, we analyzed both serious and common adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Haihuan, Zhao, Ying, Kuang, Weihong, Dai, Yanping, Cen, Xiaobo, Qin, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972296/
https://www.ncbi.nlm.nih.gov/pubmed/36865909
http://dx.doi.org/10.3389/fphar.2023.1084614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972296/
https://www.ncbi.nlm.nih.gov/pubmed/36865909
http://dx.doi.org/10.3389/fphar.2023.1084614

Ejemplares similares